Nuvectis Pharma, Inc.
NVCT
Positions held
Your positionsNVCT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $657.12M | Enterprise value | $633.71M | Trailing P/E | — | Forward P/E | -20.97 |
| PEG | — | Price / book | 59.21 | Beta | -0.24 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.1% | ROA | -73.1% | Debt / equity | — |
| Current ratio | 1.68 | Free cash flow | -$8.89M | Analyst recommendation | strong_buy | Mean target | $35.40 |
| 52w high | $29.28 | 52w low | $5.55 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$7.0M | -$6.0M | -$7.3M | -$7.5M | -$6.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.2M | -$6.3M | -$7.6M | -$7.8M | -$6.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$26.4M | -$19.0M | -$22.3M | -$19.1M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M |
Headlines — watch
• [WARN · legal] Nuvectis Pharma Says Paroxysmal Nocturnal Hemoglobinuria Drug Approved by Chinese Regulator
News
2026-09-24 · Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma
2026-09-03 · Nuvectis Pharma To Participate in Upcoming Investor Conferences
2026-08-19 · Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
2026-08-04 · Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
2026-07-29 · Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
2026-07-23 · Nuvectis Pharma Says Paroxysmal Nocturnal Hemoglobinuria Drug Approved by Chinese Regulator
Price (daily)
Full chart · RSI · MACD · patterns